Monthly Archives: October 2012

Merck and Novartis Down in Q3 Financial Reports

By Jennifer Markarian Pharmaceutical industry leaders Novartis and Merck—among others—released second-quarter 2012 results showing global sales down in third-quarter 2012, with growth in key pharmaceutical products helping to offset losses due to patent expirations.
Posted in Deals, Global, Guest Blog, leadership | Tagged , , , , | Leave a comment

Following the Pharma Money in 2012 Election

Posted in Strategy | Leave a comment

The Path of Least Resistance: Repositioned Drugs Surpass New Brands

It was in 1984 when FDA first added the 505(b)(2) pathway for drug approval, a hybrid between the accelerated pathway for generic drug applications, and the standard de novo NDA pathway for proprietary drugs. But in the past 6 years, approvals received through the 505(b)(2) pathway have consistently outnumbered de novo NDAs.
Posted in Biotech, FDA, IP, R&D, Regulatory, Strategy | Leave a comment

Obamacare After Nov 6th: Trouble for Pharma?

by Tom Norton No doubt the November 6th election is going to be close, very close: close for the Presidency, close for the Senate, and possibly close for the House.  So close, in fact, it’s possible that no substantial political change will occur in Washington, as a result. That said, for the U.S. pharmaceutical industry […]
Posted in Events, FDA, leadership, Legal, Market Access, pricing, R&D, Regulatory | Tagged , , , , | 3 Comments

Spanish Generics Industry to Government: "Leave Branded Pharma Alone"

Just days before the reports that R&D investment in Spanish pharma had fallen to below EUR1 billion ($1.3 billion) in 2011 for the first time since 2007, the country’s generic manufacturers association, AESEG, offered some unexpected support for the branded industry. In comments to APM Health Europe described as “rare”, AESEG chief Ángel Luis Rodríguez […]
Posted in Europe, Global, healthcare | Tagged , , , , , , | Leave a comment
  • Categories

  • Meta